Company Team Projects Media Contact

An innovative therapeutic approach to bacterial infection

Combioxin develops innovative anti-virulence treatments for serious bacterial infections, including those caused by antibiotic-resistant strains. The lead candidate, CAL02, is a first-in-class, clinical-stage non-antibiotic liposomal drug that neutralizes bacterial toxins, protects against infection severity and complications, and improves antibiotic efficacy.



Positive topline results from CAL02 FIM trial in the treatment of severe pneumonia - 17/04/2018

Combioxin announces completion of CAL02 FIM trial in patients with severe pneumococcal pneumomia- 29/03/2018